PMID: 3751973Aug 1, 1986Paper

Verapamil reversal of clinical doxorubicin resistance in human cancer. A Wilshire Oncology Medical Group pilot phase I-II study

American Journal of Clinical Oncology
C A PresantV Naessig

Abstract

A pilot study of the use of verapamil and adriamycin in patients with advanced malignancy was conducted to determine if the two drugs could be safely combined and to explore whether antitumor responses were frequent. The dosage of adriamycin was 50 mg/M2 every 3 weeks. Eight doses of verapamil were given orally every 6 hours, with adriamycin being administered after the fourth dose. In five patients 240 mg of verapamil taken every 6 hours produced unacceptable nausea, vomiting, hypotension, and arrhythmia. In eight patients, 120 mg of verapamil taken every 6 hours was tolerated moderately well. In four adriamycin-resistant patients, the combination of adriamycin and verapamil produced one partial response and two minor regressions. Further studies using this combination are warranted.

Citations

Jan 1, 1993·Cancer Chemotherapy and Pharmacology·K S SridharP W Benedetto
Jan 1, 1993·Cytotechnology·J M Ford, W N Hait
Jan 1, 1994·Investigational New Drugs·N H Patel, M L Rothenberg
Jan 1, 1994·Journal of Cancer Research and Clinical Oncology·E PommerenkeM Volm
Oct 1, 1991·Pharmacology & Therapeutics·E K Rowinsky, R C Donehower
Feb 28, 2001·Nature Biotechnology
Jan 1, 1996·Stem Cells·S E BatesB Chabner
Jan 1, 1990·Cancer Investigation·W T BellamyR T Dorr
Jan 1, 1990·Human Pathology·R S WeinsteinJ S Coon
Dec 1, 1990·Cancer Treatment Reviews·S B Kaye
Jan 1, 1991·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·C K van KalkenH M Pinedo
Jan 1, 1991·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S MerryS B Kaye
Mar 1, 1988·Japanese Journal of Cancer Research : Gann·T Tsuruo
Nov 30, 1993·Annals of the New York Academy of Sciences·C S Morrow, K H Cowan
Aug 1, 1993·The Journal of Urology·N ShinoharaH B Grossman
Oct 18, 2000·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·R Krishna, L D Mayer
Jan 1, 1990·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·B C BaguleyL R Ferguson
Jul 1, 1997·Current Problems in Cancer·R J MotzerW J Berg

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.